Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen -- Ignore unavailable to you. Want to Upgrade?

To: RJMC who wrote (4231)	11/26/2001 4:58:29 PM
From: Icebrg	Read Replies (3) \| Respond to of 5665

Bob, you wrote Not much news on the Abgenix or Millenium fronts. Not the right day to say things like that. MLNM issued PR this morning that they have acquired a promising colon cancer target, against which they "intend" to develop toxin-conjugated drugs. And this evening Abgenix said that they have bought the rights to an EGF-variant, which is only expressed on cancer cells. They did not say anything about conjugates in their press release. But you might remember that IMGN was testing their new taxane derivative against this type of target. Ice

To: RJMC who wrote (4231)	11/26/2001 8:02:48 PM
From: Gary Mohilner	Respond to of 5665

Bob, As Ice pointed out, new and good things are happening all the time that should benefit IMGN, we just have to be patient. I think you're general assessment of what's happening in the world and how it relates to IMGN is on the money. Time will tell, but I believe this time next year we could be celebrating the company's greatest year. Gary